Civica Rx is joining with the U.S. Department of Health and Human Services (HHS) and a team of private industry partners led by Phlow Corporation of Richmond, Virginia, to expand pharmaceutical manufacturing in the United States for use in producing medicines needed during the COVID-19 response and future public health emergencies.

The Phlow-led team will provide immediate, U.S.-based capacity to produce the active pharmaceutical ingredients and the chemical compounds for those ingredients to make critical medicines to help alleviate or prevent drug shortages, particularly during the COVID-19 pandemic.

Civica’s role will be to manufacture the finished dosage forms of essential medications, including vials and syringes, with its existing network of Civica manufacturing partners. In partnership with Phlow, Civica has already provided 1.6 million doses of critical medicines to the national stockpile for COVID-19 response. Civica will also begin to build its own finished dosage form manufacturing facility on the same site as Phlow’s other partner operations to ensure end-to-end domestic generic drug manufacturing dedicated to solving and preventing critical drug shortages.

“This partnership fits well with Civica’s mission to make essential generic medications accessible and affordable,” said Martin VanTrieste, president and CEO of Civica Rx. “We thank Phlow, VCU, and AMPAC for their collaboration and commitment to serving patients, and we thank the federal government for partnering with us to bring urgently needed advanced manufacturing capabilities for the production of essential generic drugs to the United States.”

More information about this work is available from HHS and Civica.